Dualyx Funding Round

5/15/2023

Venture Equity

$44,000,000

Series A

Use of proceeds will enable the development of the Company's lead autoimmune program DT-001, targeting TNFR2, as well as its pipeline of Treg candidates

Private & Independent

Biopharmaceutical

Technologiepark 94
Zwijnaarde, 9052
BE

Undisclosed

Dualyx is a Ghent-based biotech company dedicated to the development of novel Treg based therapies to address the needs of patients with difficult-to-treat autoimmune diseases. The company was founded in 2020 by Luc van Rompaey in a collaborative model with Wurzburg University, Argenx, VIB, Ghent University and KU Leuven. Dualyx has developed a pipeline of highly promising immune modulating programs including DT-001, an antibody agonist program targeting the TNF receptor 2 (TNFR2) which is currently in IND-enabling studies. TNFR2 is widely regarded as a master control switch in for immunosuppression, making it highly attractive for Treg therapies. Dualyx also has a pipeline of additional Treg programs in early development. Dualyx is backed by a group of well-respected investors including: Fountain Healthcare Partners, Forbion, Andera Partners, V-Bio Ventures, BGV, PMV, VIB, HTGF and GFF. ?